drugset / Trial / NCT05433857

Probiotics in Systemic Lupus Erythematosus

NCT05433857 ↗

Phase 2 Completed 40 enrolled Ain Shams University
RandomizedParallel-groupOpen-labelTreatment

Summary

Dysbiosis, or disruption of the gut microbiota, leads to the onset of autoimmunity. Increasing data suggest that the gut microbiota is changed in various murine lupus models as well as in human systemic lupus erythematosus SLE patients. Ingestion of lactobacilli, which have immunoregulatory properties, may be a viable strategy for controlling disease development and progression in patients with lupus, such as increasing the remission period and decreasing flare frequency.

Timeline

Start
2022-06-10
Primary completion
2023-12-30
Completion
2024-02-28

Drugs

EvaluationDrugModalityDoseRoute
Subject Lacteol Forte Unknown 5e+09 cells —